Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B

BACKGROUND: It is unclear whether the level of serum hepatitis B virus (HBV) DNA at baseline affects the on-treatment risk of hepatocellular carcinoma (HCC) in hepatitis B e antigen–positive (HBeAg-positive), noncirrhotic patients with chronic hepatitis B (CHB). METHODS: We conducted a multicenter c...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Won-Mook, Kim, Gi-Ae, Choi, Jonggi, Han, Seungbong, Lim, Young-Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106348/
https://www.ncbi.nlm.nih.gov/pubmed/35358094
http://dx.doi.org/10.1172/JCI154833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106348/
https://www.ncbi.nlm.nih.gov/pubmed/35358094
http://dx.doi.org/10.1172/JCI154833

Ejemplares similares